Pallawi Torka, MD
Pallawi Torka, MD
"Treat every patient like family" is my mantra. No two patients are the same and neither should be their treatment plan. When I meet a new patient for the first time, I go over their whole story in detail and analyze every minute detail of their case to ensure that together, we come up with the best plan of care, which incorporates not just cutting edge science, but also individual beliefs, and common sense. Hearing that "you have cancer" is bad enough; my goal is to walk the difficult and often confusing road with my patients and their families, and do everything I can to make the journey easier. My research focuses on lymphoproliferative cancers i.e. lymphoma and myeloma. Being part of a comprehensive cancer center such as Roswell Park Cancer Institute gives me the privilege of applying novel research principles and using promising drugs for treatment of my patients long before they are available anywhere else. I strive every day to improve the lives of people suffering from lymphoma / myeloma and hope to see an end to this scourge in my lifetime.
Landsburg DJ, Falkiewicz MK, Maly J, Blum KA, Howlett C, Feldman T, Mato AR, Hill BT, Li S, Medeiros LJ, Torka P, Hernandez-Ilizaliturri FJ, Reddy NM, Singavi A, Fenske TS, Chavez JC, Kaplan JB, Behdad A, Petrich AM, Bast MA, Vose JM, Olszewski AJ, Costa C, Lansigan F, Gerson JN, Barta SK, Calzada O, Cohen JB, Lue JK, Amengual JE, Rivera X, Persky DO, Peace DJ, Nathan S, Cassaday RD. Outcomes of patient with double-hit lymphoma who achieve first complete remission. J Clin Oncol 2017 May 5:JCO22017722157 doi: 10.1200/JCO.2017.72.2157. [Epub ahead of print]. PMID: 28475457
Torka P, Wallace P, Zhang Y, Chen G, Ho C, Balderman S, Ross M, Paiva B, Hernandez-Ilizaliturri FJ, McCarthy PL, Hahn T. Analysis of Immune Reconstitution after Autologous Hematopoietic Cell Transplant (AHCT) in Diffuse Large B-cell Lymphoma (DLBCL) and Mantle Cell Lymphoma (MCL) Patients Mobilized with Granulocyte Colony Stimulating Factor (G-CSF), with or without Plerixafor. Biology of Blood and Marrow Transplant 2016; 22(3); S155- S156
Torka P, Patel P, Tan W, Wilding G, Bhat SA, Czuczman MS, Lee KP, Deeb G, Neppalli V, Mavis C, Hernandez Ilizaliturri FJ. Augmenting Neutrophil Function By Administration of Peg-Filgrastim Potentiates Rituximab and Is Safe in Patients with Indolent B-Cell Non-Hodgkin Lymphomas: Results of a Phase II Study. Blood 2015; 126(23):3975
Gandhi S, Torka P, Hernandez-Ilizaliturri FJ. The Emerging role of Checkpoint Inhibitors in Lymphoid Malignancies. The Journal of Targeted Therapies in Cancer. 2015; 12.15: 53-62.
Torka P, Hernandez Ilizaliturri FJ, Belliotti S, Mavis C, Gu J, Czuczman MS. Inhibition of the Nuclear Factor Kappa B (NFB)/Interferon Regulatory Factor 4 (IRF4) Signaling Pathway in Activated B-cell (ABC) Diffuse Large B-cell Lymphoma (DLBCL) by Combining MLN4924, a Novel NEDD8 Activating Enzyme Inhibitor (NAE) and Ibrutinib. Blood 2014; 124(21):1768 My NCBI Link: